The extension, released shortly before the flexibilities were set to expire at the end of 2025, gives regulators more time to ...

DEA extends telemedicine prescribing flexibilities through 2026, allowing remote controlled substance prescriptions without in-person visits.

Before a lab can purchase controlled substances, the Principal Investigator (PI) must have an approved Controlled Substances Use Authorization (CSUA) Number. Only those substances which have been ...

The American Telemedicine Association announced that the U.S. Drug Enforcement Administration, or DEA, granted a 1-year extension for remote prescribing of controlled medications just before the ...

The third temporary extension, which prolongs the pandemic-era flexibilities through the end of 2025, is a relief for telehealth groups who had raised concerns about access to medications. During the ...

The Drug Enforcement Administration (DEA) published a yearlong extension of telemedicine prescribing flexibilities for controlled substances Tuesday, just one day before the end of the year, when the ...

The extension allows providers to continue remotely prescribing Schedule II–V controlled substances under specific conditions to prevent a disruptive "telemedicine cliff." ...